Brief: Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

Cosmo NV

29/03/2019 06:11

March 29 (Reuters) - Cosmo Pharmaceuticals NV  COPN.S :
    * FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017
    * FY OPERATING LOSS OF EUR 16.6 MILLION COMPARED WITH AN OPERATING LOSS OF EUR 9.6 MILLION
IN 2017
    * COSMO PHARMACEUTICALS - LOSS AFTER TAX OF EUR 18.1 MILLION, INCL. FX GAIN OF EUR 5.4
MILLION ON
OUR US$ LIQUIDITY POSITION (LOSS AFTER TAX OF EUR 32.5 MILLION IN 2017)
    * NET PROCEEDS OF EUR 163.4 MILLION RAISED THROUGH ISSUE OF A CONVERTIBLE BOND
    * IN 2019 EXPECTS TO REDUCE OPERATING LOSSES COMPARED TO 2018 TO A LEVEL OF APPROX. EUR 12M
    * EXPECTS TO RETURN TO PROFITABILITY IN 2020, DELAY BEING CAUSED BY NON-APPROVAL OF
METHYLENE BLUE
MMX

Source text for Eikon:  ID:nTENkhboya 
Further company coverage:  COPN.S 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))